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To the Editor:
The understanding of soft tissue sarcoma has
progressed impressively in the last two decades.
Delineation of the biology, molecular diagnosis, and
outcome have been carefully characterized with de-
ﬁned prognostic indicators. The challenge has been to
identify if biology can predict behavior; that has now
been clearly established. More importantly, can
biology and predictive outcome mandate treatment
change, and ﬁnally can treatment, based on biology
and known outcome, be altered to reﬂect improved
outcome?
Dr Pollock and his coauthors examine this ques-
tion by deﬁning retroperitoneal liposarcoma into
well-diﬀerentiated (WD) and dediﬀerentiated (DD)
subtypes.
1 They examined 135 patients over the last
10 years at their institution. This signiﬁcant experi-
ence in a major sarcoma center allows important
observations. As expected, WD was mostly primary
and DD was mostly recurrent. Chemotherapy was
rarely used in WD, and more aggressive resection
was required in DD, while a third to half of all
patients required multivisceral resection. The initial
complete gross resection was obtained in both
groups, and, as expected, recurrence was greater in
the dedifferentiated group. As previously identiﬁed,
metastatic disease is rare in well-differentiated lipo-
sarcoma and local recurrence can be late and pro-
longed.
While the title of the present manuscript, ‘‘Two
Diﬀerent Diseases Possibly Requiring Diﬀerent
Treatment Approaches,’’ is most enticing, the data
predominantly conﬁrm that accurate diagnosis of
histological subtype predicts recurrence. A recent
nomogram based on 800 patients with liposarcoma
has conﬁrmed the importance of histological sub-
type.
1 Few would challenge the authors questioning
of whether, with such different outcomes, treatment
should be different; however, how different is differ-
ent? The real challenge, alluded to in the title, is what
‘‘different’’ treatment should be applied to these
‘‘different’’ diseases. The authors are clearly aware of
the different outcomes, and that has already affected
management. In both groups radiation is minimally
used (\20%), whereas chemotherapy is essentially
never used in the well-differentiated type and used in
the dedifferentiated type in the majority (73%).
However, the beneﬁts of such different approaches
are unclear. Despite aggressive use of multimodality
therapy, outcome remains poor with 5-year survival
in DD at 37%. This is similar to that reported by
Dalal et al. at 39%.
2
Unfortunately, the real challenge remains; we can
increasingly improve the accuracy of histological
diagnosis, molecular characterization, and predic-
tion of outcome, but we are far less sanguine about
improvements in treatment that translate into better
survival. Importantly, the reverse is true. We are
now aware that we can diminish the aggressivity of
surgical approaches when the biology is favorable
and the consequence of recurrence limited. The
authors conﬁrm that less aggressive surgical
approaches for WD are appropriate. The presence
of WD liposarcoma especially an asymptomatic lo-
cally recurrent lesion does not mandate operation! It
is fortunate that our knowledge increases and
unfortunate that we cannot transfer that increase of
knowledge into more eﬀective therapy. We take
some consolation in the fact that we can decrease
morbidity of surgical therapy by better understand-
ing of biology.
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